Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.60 |
| ▸ | ARG2 | P78540 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1531672 | 1.00 | ARG1 (0.60) | ARG1ARG2SMN1; SMN2HIF1AMEN1 | |
| SCHEMBL29278348 | 1.00 | ARG1 (0.60) | ARG1ARG2SMN1; SMN2HIF1AMEN1 | |
| SCHEMBL7902168 | 0.88 | ARG1 (0.59) | ARG1ARG2SMN1; SMN2HIF1AMEN1 | |
| SCHEMBL1819025 | 0.86 | BLM (0.56) | ARG1ARG2SMN1; SMN2HIF1AMEN1 | |
| SCHEMBL22689266 | 0.85 | ARG1 (0.79) | ARG1ARG2SMN1; SMN2HIF1ASLC6A2 | |
| SCHEMBL8351006 | 0.85 | SMN1; SMN2 (0.69) | ARG1ARG2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL7653153 | 0.84 | ARG1 (0.62) | ARG1ARG2SMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL14478223 | 0.82 | ARG1 (0.60) | ARG1ARG2SMN1; SMN2HIF1AMEN1 | |
| SCHEMBL27469449 | 0.82 | ARG1 (0.60) | ARG1ARG2SMN1; SMN2HIF1AMEN1 | |
| SCHEMBL11265744 | 0.81 | HIF1A (0.60) | ARG1ARG2SMN1; SMN2HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112585690-A | System and method for producing individualized individual unit doses containing a pharmaceutically active substance | 阿奎斯蒂弗医疗股份有限公司 | 2021-03-30 | — | — | CN | claimed |
| EP-1781210-B1 | COMPOSITE VASCULAR GRAFT INCLUDING BIOACTIVE AGENT COATING AND BIODEGRADABLE SHEATH | BOSTON SCIENT LTD (BB) | 2013-01-16 | — | — | EP | claimed |
| EP-1372530-B1 | STENT WITH CONTROLLED EXPANSION | BOSTON SCIENT LTD (BB) | 2006-02-08 | — | — | EP | claimed |
| US-6766071-B2 | Device and method for the measurement of the heat of a reaction | AMERSHAM BIOSCIENCES UK LTD. (GB) | 2004-07-20 | — | — | US | claimed |
| US-6762277-B2 | REACTING AMINO ACIDS WITH DI-TERT-BUTYLTRICARBONATE THEN DECARBOXYLATING; FOR USE IN PRODUCING FIBER MATERIALS, LIQUID CRYSTAL MATERIALS, OPTICAL MATERIALS, AND BIOCOMPATIBLE MATERIALS | JSR CORPORATION (JP) | 2004-07-13 | — | — | US | claimed |
| US-20030095735-A1 | Device and method for the measurement of the heat of a reaction | GE HEALTHCARE UK LIMITED (GB) | 2003-05-22 | — | — | US | claimed |
| CN-118414150-A | Pharmaceutical composition with enhanced stability characteristics | 阿奎斯蒂弗医疗股份有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118302172-A | Dry powder foamable formulation for delivery of drugs via mucous membranes | 查德威克·唐纳森 | 2024-07-05 | — | — | CN | disclosed |
| US-12023309-B2 | Enhanced delivery epinephrine compositions | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240189355-A1 | HYPOIMMUNOGENIC CELLS HAVING TARGETED MODIFICATIONS IN MHC CLASS-I GENES AND METHODS OF USE | WUGEN, Inc. | 2024-06-13 | — | — | US | disclosed |
| WO-2024107742-A1 | HYPOIMMUNOGENIC CELLS HAVING TARGETED MODIFICATIONS IN MHC CLASS-I GENES AND METHODS OF USE | WUGEN, Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240148673-A1 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| CN-117440807-A | Apixaban film products and uses thereof | 泰合生技药品股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| WO-1995008563-A1 | GLUTATHIONE ANALOGS AND PARALOG PANELS COMPRISING GLUTATHIONE MIMICS | TERRAPIN TECHNOLOGIES, INC. (US) | 1995-03-30 | — | — | WO | disclosed |
| EP-0645397-A1 | Glutathione analogs and paralog panels comprising glutathione mimics | TERRAPIN TECHNOLOGIES, INC. (US) | 1995-03-29 | — | — | EP | disclosed |
| WO-1994002450-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| EP-0073143-B1 | NOVEL COMPLEX AMIDO AND IMIDO DERIVATIVES OF CARBOXYALKYL PEPTIDES AND THIOETHERS AND ETHERS OF PEPTIDES | Ryan, James Walter (US) | 1985-11-21 | — | — | EP | disclosed |
| EP-0073143-A2 | Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides | Ryan, James Walter (US) | 1983-03-02 | — | — | EP | disclosed |
| EP-0048159-A2 | Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents | UNIVERSITY OF MIAMI (US) | 1982-03-24 | — | — | EP | disclosed |
| US-3952193-A | Imaging method with U.V. excitation of liquid crystal | XEROX CORPORATION (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148673-A1 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | ADRA1B, ADRB1, ADRA2C | ARG1 2425/4885ARG2 3047/4885SMN1; SMN2 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.